Prestige Consumer Healthcare (PBH) Margin Slippage Tests Bullish Valuation Narratives In FY 2026

Prestige Consumer Healthcare (PBH) closed out FY 2026 with fourth quarter revenue of US$281.6 million and basic EPS of US$1.14, alongside trailing twelve month revenue of US$1.09 billion and EPS of US$3.93 that outline the full year earnings picture. Over recent quarters the company has seen revenue range from US$249.5 million to US$296.5 million and quarterly EPS move between US$0.86 and US$1.23. This gives you a clear view of how the top and bottom line have tracked into the latest result. With a trailing net profit margin of 17.5%, the update keeps the focus firmly on how efficiently the business is converting sales into profit.

See our full analysis for Prestige Consumer Healthcare.

With the headline numbers on the table, the next step is to see how this earnings profile lines up with the prevailing bull, bear and consensus narratives around Prestige Consumer Healthcare.

See what the community is saying about Prestige Consumer Healthcare

TTM earnings ease back to US$190.3 million

• On a trailing basis, net income sits at US$190.3 million on US$1.09b of revenue, versus US$214.6 million on US$1.14b a year earlier, alongside a net margin shift from 18.9% to 17.5%.
• Consensus narrative highlights supply chain fixes and e-commerce growth as long term supports, which sits against the fact that trailing net income and margins are both below last year. Investors may want to see how quickly initiatives like the Pillar5 acquisition and stronger international demand translate into higher profit on that roughly US$1.09b revenue base.
  • Stronger consumption trends in areas like women’s health and international markets are part of the bullish case. However, the current 17.5% margin shows that some of that demand is not fully flowing through to profit compared with the 18.9% level cited a year ago.
  • Management focus on cost control and pricing is a key part of the optimistic story, but with trailing net income at US$190.3 million versus US$214.6 million a year ago, readers can treat FY 2026 as a real world test of how resilient those levers are under pressure.

To see how these trailing figures line up with longer term growth, risks, and valuation views, it is worth checking the community’s full take on the stock, including how today’s numbers fit into wider narratives about self care demand and brand strength.📊 Read the what the Community is saying about Prestige Consumer Healthcare.

P/E of 11.4x and 17.5% margin

• The stock trades on a 11.4x P/E against a TTM net margin of 17.5%, compared with a US Pharmaceuticals industry average P/E of 15.3x and a peer average of 16.2x, which frames Prestige as priced below those groups on this metric.
• Consensus narrative points to consistent cash generation and disciplined costs as supports for long term EPS. Yet the combination of a lower margin than last year and a discounted 11.4x P/E means the market is currently assigning a lower multiple than industry and peer benchmarks despite those cash flow arguments.
  • Investors weighing the bullish angle on margin stability can compare it directly with the margin move from 18.9% to 17.5% over the last year and ask whether the current P/E discount already builds that in.
  • The view that cost control can underpin future EPS also sits alongside the note that the company carries a high level of debt, so some readers may connect the lower P/E with a desire for more clarity on how that leverage interacts with earnings quality.

DCF fair value and US$74.20 target

• The DCF fair value cited in the analysis is US$164.53 per share and the analyst price target is US$74.20, compared with a current share price of US$45.93. These are two different reference points investors can compare against the same FY 2026 earnings base.
• Supportive views highlight steady free cash flow and expectations for earnings growth, while more cautious investors point to the margin step down and high debt. The gap between the US$45.93 share price, the US$74.20 target and the US$164.53 DCF fair value encourages readers to decide how much weight to give to those models versus the recent pullback in TTM net income from US$214.6 million to US$190.3 million.
  • Those who focus on the reward side may see the difference between 11.4x P/E and peer multiples above 16x as consistent with the higher DCF fair value and target, but they still have to be comfortable with earnings slipping over the last twelve months.
  • Investors who are more cautious can treat the combination of high debt, a slightly lower 17.5% margin and those higher valuation markers as a prompt to stress test their own assumptions before relying on any single fair value figure.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Prestige Consumer Healthcare on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Uncertain about how to balance the risks and rewards highlighted here? Move quickly from reading to testing the data yourself and see how the story stacks up against the 4 key rewards and 1 important warning sign.

See What Else Is Out There

The recent results show net income easing back from US$214.6 million to US$190.3 million and margins softening from 18.9% to 17.5%, alongside concerns around high debt.

If that mix of softer earnings and leverage is making you cautious, you can compare this profile with companies filtered through the solid balance sheet and fundamentals stocks screener (45 results) to quickly focus on financially sturdier ideas.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com